Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.
Unbeatable Production Arbitrage
Ultra-Low Costs: All-in production costs of €0.30 per gram, with further downward pressure expected as the facility scales toward its 25+ tonne licensed capacity.
Elite Genetics: Proven high-THC cultivars (mid-20% THC) featuring advanced terpene profiles tailored for European and Australian markets.
Ideal Climate: Located in a premium microclimate with stable, predictable conditions enabling year-round cultivation.
Institutional-Grade Infrastructure & Scalability
Immediate Capacity: 1.7 hectares of interconnected greenhouses currently producing 5.7 tonnes of dried flower annually.
Expansion Ready: Fully licensed 15-hectare site with capacity for 25+ tonnes, enabling significant scale-up with minimal additional capex.
Operational Autonomy: Dedicated on-site power substation with diesel backup and a 20,000 m³ rainwater reservoir supported by a sophisticated water treatment system.
Advanced Post-Harvest & Processing Technology
Dual-Track Facility: Separate buildings for GACP post-harvest and EU-GMP / TGA GMP-compliant processing.
Unique Technology Edge: Includes Colombia’s only PLC 2500 purification system and an X-ray sterilization unit required for the Australian market.
On-Site Laboratory: Fully equipped lab enabling real-time potency and purity testing to ensure pharmaceutical-grade standards.
Validated Global Export Track Record
Proven Market Access: One of the few Colombian producers with established exports; approximately 1 tonne already delivered to European markets.
De-Risked Revenue: Sale includes a binding 3-year offtake agreement and established distribution relationships in Germany and the UK.
Turnkey Transition & Strategic Value
Investment Value: Over USD $12M already invested in infrastructure, licensing, and elite genetics.
Financial Status: Debt-free; all related-party debt is forgiven at closing.
Shortcut to Market: Bypasses the typical 3-year development cycle including site selection, construction, and regulatory approvals in Colombia.
Management Continuity: Core leadership team, including production specialists, will remain to ensure a seamless operational transition.
Tax Efficiency: Tax loss carryforwards (~USD $1.5M) available through 2036, preserved under the share sale structure.
